Enliven Therapeutics

Yahoo Finance • 15 days ago

Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market

Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 11 Stocks With 3x-5x Returns This Year. Enliven Therapeutics has seen its stock price soar by 194 percent year-to-date, at $45.34 versus $15.40 on December 31, with investor sentiment... Full story

Yahoo Finance • 26 days ago

Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 26, H.C. Wainwright increased its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $48 to $56 and kept its B... Full story

Yahoo Finance • last month

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics(NASDAQ:ELVN), reported the exercise of 40,000 stock options for Common Stock and immediate sale of those shares for proceeds of approximately ~$1.20 million, according to... Full story

Yahoo Finance • 5 months ago

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors

Key Points New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable ass... Full story

Yahoo Finance • 9 months ago

What's going on in today's pre-market session

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMME... Full story

Yahoo Finance • 9 months ago

Terns Pharmaceuticals’ SWOT analysis: obesity drug stock poised for pivotal data

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s stock has garnered significant attention from analysts and inv... Full story

Yahoo Finance • 9 months ago

Enliven files automatic mixed securities shelf

* Enliven Therapeutics (NASDAQ:ELVN [https://seekingalpha.com/symbol/ELVN]) filed automatic mixed securities shelf. * Filing [https://seekingalpha.com/filing/10301128] MORE ON ENLIVEN THERAPEUTICS * Enliven Therapeutics stock falls... Full story

Yahoo Finance • 9 months ago

Enliven Therapeutics, Inc Q2 Loss Climbs

(RTTNews) - Enliven Therapeutics, Inc (ELVN) revealed Loss for its second quarter of -$25.34 million The company's bottom line totaled -$25.34 million, or -$0.49 per share. This compares with -$19.95 million, or -$0.41 per share, last ye... Full story

Yahoo Finance • 9 months ago

Enliven Therapeutics CSO sells $278k in shares

Joseph P Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a $1.31 billion market cap biotechnology company, sold a total of 12,500 shares of common stock on July 21, 2025, according to a Form 4 filing with... Full story

Yahoo Finance • 10 months ago

Enliven Therapeutics COO Patel sells shares worth $131950

Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a $1.28 billion market cap biotech company with strong financial health metrics according to InvestingPro, sold shares of the company’s common stock on July... Full story

Yahoo Finance • 10 months ago

TD Cowen reiterates buy rating on Enliven Therapeutics stock

Investing.com - TD Cowen maintained its buy rating on Enliven Therapeutics (NASDAQ:ELVN) stock in a research note released Friday. The $1.29 billion market cap company, which has received a strong buy consensus from analysts with price tar... Full story

Yahoo Finance • 10 months ago

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at Goldman Sachs started coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) with a Buy rating and a $37.00 price target, imply... Full story

Yahoo Finance • 11 months ago

Goldman Sachs initiates Enliven Therapeutics stock with Buy rating

Goldman Sachs initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) Monday with a Buy rating and a $37.00 price target, citing positive Phase 1 data for the company’s chronic myeloid leukemia (CML) treatment. The biotech company, curren... Full story

Yahoo Finance • 11 months ago

Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares

(RTTNews) - Enliven Therapeutics, Inc. (ELVN), a company focused on the discovery and development of small molecule therapeutics, said on Friday that it has commenced an underwritten public offering of $200 million of shares and, in lieu o... Full story

Yahoo Finance • 11 months ago

Enliven price target lowered to $27 from $36 at JonesResearch

JonesResearch analyst Soumit Roy lowered the firm’s price target on Enliven (ELVN) to $27 from $36 and keeps a Buy rating on the shares. The company’s abstract from the Phase 1 late line chronic myeloid leukemia trial with ELVN-001 “was me... Full story

Yahoo Finance • 2 years ago

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) and noted the company as an emerging biotech compa... Full story

Yahoo Finance • 2 years ago

Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable securities, which is expected to provide cash... Full story